Krystal Biotech, Inc. (KRYS) Misses Q1 EPS by 26c, provides guidance

Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q1 EPS of $1.20, $0.26 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $88.18 million versus the consensus estimate of $99.12 million.

FY 2025 Guidance:
Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expense(1) $150.0 - $175.0

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley Upgrades Demant A/S (DEMANT:DC) (WILYY) to Overweight